## Contents

**EDITORIAL**

1544  Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype  
*Jeong KY, Lee H*

**OPINION REVIEW**

1551  New drugs for the treatment of metastatic colorectal cancer  
*Cherri S, Libertini M, Zaniboni A*

**REVIEW**

1561  Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer  
*Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S*

1599  Radiomics in hepatocellular carcinoma: A state-of-the-art review  
*Yao S, Ye Z, Wei Y, Jiang HY, Song B*

1616  Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment  

1632  Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer  
*Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA*

1648  Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers  
*Lv X, Xu G*

**MINIREVIEWS**

1668  Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway  
*Yang Y, Zhang ZJ, Wen Y, Xiong L, Huang YP, Wang YX, Liu K*

1680  Liver tumors in children with chronic liver diseases  
*Sintusek P, Phewplung T, Sampavat A, Poovorawan Y*

1696  Non-surgical treatment of hilar cholangiocarcinoma  
ORIGINAL ARTICLE

Basic Study

1709  Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis

Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ

1725  Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma


1741  Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmylocytic polypeptide-expressing metaplasia lesions

Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP

1755  Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved

Chen Y, Liu FX, Liu H

Case Control Study

1766  Genetic variation of TGF-BR2 as a protective genotype for the development of colorectal cancer in men

Stanilov N, Grigorova A, Velikova T, Stanilova SA

Clinical Trials Study

1781  Induction chemotherapy with albumin-bound paclitaxel plus lobarplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK

SYSTEMATIC REVIEWS

1791  Colorectal cancer in Arab world: A systematic review


1799  Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review

Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J

1813  Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review


META-ANALYSIS

1833  Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis

Liu H, Hu FJ, Li H, Lan T, Wu H
LETTER TO THE EDITOR

Hepatocellular carcinoma biomarkers, an imminent need

Zamora-León SP
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology, School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.
Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway

Yang Yang, Zi-Jian Zhang, Yu Wen, Li Xiong, Yun-Peng Huang, Yong-Xiang Wang, Kai Liu

ORCID number: Yang Yang 0000-0002-8136-6893; Zi-Jian Zhang 0000-0003-4041-9263; Yu Wen 0000-0001-7444-3021; Li Xiong 0000-0002-5570-0229; Yun-Peng Huang 0000-0002-0578-1235; Yong-Xiang Wang 0000-0001-8966-0010; Liu Kai 0000-0003-3938-2993.

Author contributions: Yang Y and Zhang ZJ equally to this work; Zhang ZJ and Yang Y designed and wrote the paper; Huang YP, Liu K and Wang YX edited the work; Xiong L and Wen Y reviewed and revised the manuscript.

Supported by The National Natural Science Foundation of China, No. 81970569 and 81773293; Natural Science Foundation of Hunan Province, No. 2017SK50121.

Conflict-of-interest statement: The authors declare that they do not have any conflicting interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works

Abstract

Pancreatic cancer is a highly lethal malignancy with low resection and survival rates and is not sensitive to radiotherapy and chemotherapy. Ferroptosis is a novel form of nonapoptotic regulated cell death characterized by the accumulation of lipid peroxides and reactive oxygen species involved in iron metabolism. Ferroptosis has a significant role in the occurrence and development of various tumors. Previous studies have shown that regulating ferroptosis-induced cell death inhibited tumor growth in pancreatic cancer and was synergistic with other antitumor drugs to improve treatment sensitivity. Herein, we discuss the mechanism, inducers, and developments of ferroptosis in pancreatic cancer to provide new strategies for the treatment of the malignancy.

Key Words: Pancreatic cancer; Ferroptosis; Reactive oxygen species; Iron metabolism; Lipid peroxides

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Many studies have confirmed that ferroptosis is closely related to the occurrence and development of pancreatic cancer, but there are few systematic reviews on the mechanism and treatment of ferroptosis in pancreatic cancer. This review focuses on the research progress of the mechanism of ferroptosis in pancreatic cancer, and summarizes feasible treatment from the perspective of the processes leading to the occurrence of ferroptosis.

Ferroptosis is a novel form of nonapoptotic regulated cell death (RCD) [8] characterized by the accumulation of lipid peroxides and reactive oxygen species (ROS) involved in iron metabolism [9]. ROS react with polyunsaturated fatty acids (PUFAs) in the lipid membrane to generate excessive amounts of lipid peroxides, resulting in cell membrane damage and eventually ferroptosis. Studies have shown that ferroptosis is involved in the occurrence and development of various diseases, such as neuropathy [10], ischemia-reperfusion injury [11], acute renal failure [12], and cancer. A study reported that ferroptosis might be a common and dynamic form of RCD in the treatment of cancer [13].

More than 90% of PDAC patients have mutations in the KRAS gene that promotes proliferation, alters cellular metabolism, and affects invasion and autophagy [14]. Mutations in KRAS lead to a significant increase in intracellular ROS [15]. To avoid cell death, cancer cells must promptly remove intracellular ROS during rapid division. A study reported that PDAC cells transport a large amount of cystine/cysteine to synthesize glutathione (GSH) as a compensatory mechanism, thereby eliminating excess intracellular ROS [16]. Ferroptosis is closely related to the production of cysteine/cysteine and ROS and thus can be considered a critical form of RCD in PDAC and might be selectively targeted as an anticancer therapy. In this review, we briefly describe the mechanism of ferroptosis, its research status, and prospects for use in treating PDAC.

PROFILE AND RESEARCH PERSPECTIVE OF FERROPTOSIS

Origin
In 2003, Dolma et al. [17] discovered an antitumor drug named erastin that induced cell death without causing changes in nuclear morphology, DNA fragmentation, and caspase 3 activation. Moreover, caspase inhibitors did not reverse the process. Subsequently, the group identified RAS-selective lethal small molecule 3 (RSL3), which induced cell death similar to that caused by erastin [18]. In 2012, Dixon et al. [8] found that erastin inhibited the cystine/glutamate antiporter (system XC-), causing excessive accumulation of lipid ROS, ultimately leading to an iron-dependent oxidative death known as ferroptosis.

Characteristics
Compared with other RCDs such as necrosis, apoptosis, and autophagy [19] (Table 1),
Ferroptosis is characterized by the maintenance of an intact nucleus, nonaggregation of chromatin, nonrupture and foaming of the protoplasm membrane, condensed mitochondrial membrane densities, reduction or loss of mitochondrial cristae, and outer mitochondrial membrane rupture[9]. The biochemical characteristics of ferroptosis are increased concentration of lipid hydrogen peroxide (H₂O₂) and ferrous iron (Fe²⁺). Intracellular lipid oxidizes are abnormally metabolized by the catalysis of iron ions, and the increased lipids production affects the original redox balance. Thus, the biological macromolecules are attacked, leading to cell death manifested by the inactivation of glutathione peroxidase 4 (GPX4) and deposition of lipid peroxide[20].

### Main metabolic process of ferroptosis
Currently, the metabolic mechanism of ferroptosis is known to include three processes. (1) Iron metabolism includes participation of iron ions in the formation of ROS through enzymatic or non-enzymatic reactions to mediate ferroptosis; (2) Amino acid metabolism includes GSH, which is a substrate of GPX4. GSH is the most important intracellular antilipid oxidation molecule. Cysteine is the raw material required for its synthesis, and an abundance of intracellular cysteine determines the synthesis of GSH and the process of cellular resistance to lipid oxidation, ultimately affecting ferroptosis[21,22]; and (3) Lipid metabolism is involved. The accumulation of lipid peroxides, especially phospholipid peroxides, is considered a landmark of ferroptosis[23]. A recent study reported that ferroptosis suppressor protein 1 exists as an independent parallel system that cooperates with GPX4 and GSH to suppress phospholipid peroxidation and ferroptosis[24]. Furthermore, induction of ferroptosis occurs by regulating the tumor microenvironment (Figure 1).

### CURRENT STATUS OF FERROPTOSIS IN PDAC
In recent years, systemic treatment of PDAC has mainly relied on 5-fluorouracil and gemcitabine-based therapy. However, because of rapid and widespread development of chemical resistance, the prognosis remains poor. Recent studies have demonstrated that ferroptosis is associated with PDAC (Figure 2). Therefore, inducing ferroptosis is a new strategy to combat PDAC.

**Ferroptosis regulated by iron metabolism in PDAC**
Extracellular ferric ions (Fe³⁺) form a conjugate with transferrin and are transported via the transferrin receptor 1 on the surface of the cell membrane. First, the conjugate enters the cell by endocytosis. Subsequently, Fe³⁺ are reduced by the six-transmembrane epithelial antigen of prostate 3 to Fe²⁺ and enter the cytoplasm from the endosome via the divalent metal ion transporter 1[25]. Fe²⁺ can be stored as ferritin or in the free form. Meanwhile, ferritin, as a downstream regulatory gene of nuclear factor erythroid 2-related factor 2 (NRF2), is regulated by the p62-KEAP1-NRF2 signaling pathway[26] (Figure 2).

Excess intracellular Fe²⁺ catalyzes the Fenton reaction, in which Fe²⁺ reacts with H₂O₂ to produce Fe³⁺ and hydroxyl radicals. The hydroxyl radical is a type of ROS that can damage proteins, lipids, and DNA, affect the function of cell membranes, and lead to cell death[26]. From the perspective of chemical reactions of intracellular Fe²⁺, the Fenton reaction may be considered one of the important processes involved in ferroptosis. The reaction between H₂O₂ and Fe²⁺ generates Fe³⁺ along with OH⁻ and hydroxyl radicals (Formula 1). The hydroxyl radical is one of the most active ROS. In addition, the Fenton reaction can generate peroxy free radicals[27] (Formulas 2 and 3).

### Table 1 Features of ferroptosis and other forms of regulated cell death

<table>
<thead>
<tr>
<th>Ferroptosis</th>
<th>Necrosis</th>
<th>Apoptosis</th>
<th>Autophagy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Morphological features</strong></td>
<td>Condensed mitochondrial membrane densities, reduction or vanishing of mitochondria cristae, and outer mitochondrial membrane rupture</td>
<td>Organelle swelling, plasma membrane damage, cell disruption</td>
<td>Cell membrane foaming, cell shrinkage and the formation of apoptotic bodies</td>
</tr>
<tr>
<td><strong>Biochemical features</strong></td>
<td>Iron accumulation; lipid peroxidation; glutaminolysis</td>
<td>Activation of RIP1, RIPK3, and MLKL; activation of inflammasome and release of pro-inflammatory cytokines</td>
<td>DNA fragmentation; Caspases cascade activation; Ca²⁺/mg²⁺-dependent endogenous nuclease and calpain activation</td>
</tr>
</tbody>
</table>

**Main metabolic process of ferroptosis**
Currently, the metabolic mechanism of ferroptosis is known to include three processes. (1) Iron metabolism includes participation of iron ions in the formation of ROS through enzymatic or non-enzymatic reactions to mediate ferroptosis; (2) Amino acid metabolism includes GSH, which is a substrate of GPX4. GSH is the most important intracellular antilipid oxidation molecule. Cysteine is the raw material required for its synthesis, and an abundance of intracellular cysteine determines the synthesis of GSH and the process of cellular resistance to lipid oxidation, ultimately affecting ferroptosis[21,22]; and (3) Lipid metabolism is involved. The accumulation of lipid peroxides, especially phospholipid peroxides, is considered a landmark of ferroptosis[23]. A recent study reported that ferroptosis suppressor protein 1 exists as an independent parallel system that cooperates with GPX4 and GSH to suppress phospholipid peroxidation and ferroptosis[24]. Furthermore, induction of ferroptosis occurs by regulating the tumor microenvironment (Figure 1).
Figure 1 Metabolic mechanisms of ferroptosis in pancreatic ductal adenocarcinoma. A: Lipid metabolism; B: Iron metabolism; C: Autophagy; D: Amino acid metabolism. ACSL4: Long-chain acyl-CoA synthetase 4; ALOXs: Arachidonate lipooxygenases; ATG5: Autophagy-related 5; ATG7: Autophagy-related 7; CoQ10: Coenzyme Q10; CoQ10H2: Ubiquinol-10; DIAPH3: Diaphanous homolog 3; FSP1: Ferroptosis suppressor protein 1; GPX4: Glutathione peroxidase 4; GSH/GSSG: Glutathione; KEAP1: Kelch-like ECH-associated protein 1; LPCAT3: Lysophosphatidylcholine acyltransferase 3; LTF: Lactotransferrin; NAD(P)H: Nicotinamide adenine dinucleotide phosphate; NCOA4: Nuclear receptor coactivator 4; NEDD4L: Neural precursor cell-expressed developmentally downregulated 4-like; NRF2: Nuclear factor erythroid 2-related factor 2; P62/SQSTM1: Sequestosome 1; PIR: Pirin; PUFA: Polyunsaturated fatty acids; ROS: Reactive oxygen species; SLC3A2: Solute carrier family 3 member 2; SLC7A11: Solute carrier family 7 member 11; STEAP3: Six-transmembrane epithelial antigen of the prostate 3; TF: Transferrin; TnR1: Thioredoxin reductase 1.

Figure 2 Iron transport. DMT1: Divalent metal transporter 1; LCN2: Lipocalin-2; LTF: Lactotransferrin; NEDD4L: Neural precursor cell-expressed developmentally downregulated 4-like. SD: Siderophore; STEAP3: Six-transmembrane epithelial antigen of the prostate 3; TFR1: Transferrin receptor 1; TFR2: Transferrin receptor 2.

The series of reactions suggest that iron ions act as a catalyst to promote the production of ROS in cells, especially in tumor cells. Therefore, the Fenton reaction not only provides Fe2+ but also continuously catalyzes the production of ROS, both of which are essential conditions for ferroptosis. Formulas: (1) Fe2+ + H2O2 → Fe3+ + (OH-) + OH (Formula 1); (2) O2 + Fe3+ → O2 + Fe2+ (Formula 2); and (3) O2 + Fe2+ + Fe3+ + O2 (Formula 3).
Ferritin is composed of two subunits, namely ferritin heavy chain (FHC) and ferritin light chain (FLC). A study reported that iron-responsive element-binding protein 2 increased the expression of FHC and FLC to inhibit ferroptosis[29]. Lactotransferrin (LTF) is a member of the transferrin family that is associated with increased intracellular iron during inflammatory injury and is by neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L). Wang et al[30] reported that NEDD4L-mediated LTF protein degradation inhibited intracellular iron accumulation and subsequent oxidative damage-mediated ferroptosis in PDAC. Lipocalin-2 (LCN2) interacts with siderophores (iron-binding proteins) and acts as an iron carrier to intracellular and extracellular iron levels. Another study reported that LCN2 inhibited invasion and angiogenesis in PDAC[31].

**Autophagy-dependent ferroptosis in PDAC**

The autophagic degradation of ferritin to release Fe²⁺ is known as ferritinophagy, which is mediated by nuclear receptor coactivator 4 (NCOA4)[32]. Ferritinophagy is closely associated with the physiological and pathological processes of cell growth, proliferation, differentiation, apoptosis, and carcinogenesis. Under physiological conditions, ferritinophagy is tightly regulated by the iron-dependent protein network to maintain the balance of iron in cells and perform its functions. However, excessive activation of ferritinophagy leads to intracellular iron overload and accumulation of a large amount of ROS in a short period, resulting in ferroptosis. Therefore, it has been proposed that ferroptosis is a type of autophagy-dependent cell death[33].

Overexpression of NCOA4 enhances the degradation of ferritin, increases intracellular free iron levels, and promotes ferroptosis. Knockout or knockdown of autophagy-related 5 (ATG5) and ATG7-limited erastin-induced ferroptosis are associated with decreased intracellular Fe²⁺ levels and lipid peroxidation. Hou et al[32] further found that activating the ATG5/7-NCOA4 axis inhibited the expression of FHC and degraded ferritin, leading to an increase in intracellular Fe²⁺ and lipid ROS, thereby promoting ferroptosis in PDAC. Zhu et al[34] reported that heat shock protein 5 (HSPA5) is closely related to the prognosis of PDAC patients treated with gemcitabine. Activation of the HSPA5-GPX4 pathway led to the resistance of PDAC cells to gemcitabine. Inhibition of HSPA5 or GPX4 gene expression reversed the resistance and ferroptosis played an important role in the process. NRF2 is a transcription factor that regulates heme and iron metabolism. Pirin (PIR), an iron-binding nuclear protein, is a nuclear redox sensor and regulator. Overexpression of PIR limits oxidative damage to DNA, subsequent cytoplasmic transport, and extracellular release of high mobility group box protein 1, which is released by ferroptotic cells and subsequently triggers an inflammatory response in peripheral macrophages. NRF2 mediates the upregulation of PIR leading to autophagy-dependent ferroptosis[35,36]. In addition, the ferroptosis inducers erastin, sorafenib[37], and sulfasalazine[38], (Table 2) have been shown to activate the adenosine monophosphate-activated protein kinase/sterol regulatory element-binding protein 2 signaling pathway through iron-dependent ferritinophagy [39]. Furthermore, a phase I study revealed that the combination of sorafenib and gemcitabine demonstrated promising antitumor activity in patients with advanced PDAC[40]. However, the combination therapy did not improve recurrence-free and overall survival of patients with PDAC with postsurgical R1 residual status. However, a subgroup analysis revealed significantly improved disease-free and overall survival of patients who underwent more than six cycles of chemotherapy. Twelve cycles of additive chemotherapy with gemcitabine may be considered for patients in poor general health[41]. Therefore, research on the relationship between autophagy and ferroptosis may provide new ideas for the treatment of PDAC.

**Ferroptosis is regulated by amino acid and GSH metabolism in PDAC**

Cellular entry and exit of cysteine and glutamic acid require a specific transporter, system XC-, which is a heterodimer formed by the glycosylated heavy chain CD98hc, which is also called solute carrier family 3 member 2 (SLC3A2), and nonglycosylated xCT (SLC7A11) joined by disulfide bonds[42]. Cystine is reduced to cysteine to synthesize GSH and regulate downstream lipid peroxidation. As an electron donor, GSH converts toxic phospholipid peroxides into nontoxic phospholipid alcohols and oxidized glutathione under the action of GPX4[43]. In addition to system XC-, cysteine can be transported directly into the cell by the alanine-serine-cysteine system, which is also known to inhibit ferroptosis[44]. Furthermore, cystine can be synthesized from methionine via the transulfuration pathway.

Many cells rely on system XC- for cystine uptake, which is the rate-limiting step for cysteine synthesis. Blocking or inhibiting this step leads to a decrease in intracellular cysteine, inhibits the lipid repair function of GPX4, and ultimately induces ferroptosis.
## Table 2 Ferroptosis inducers in pancreatic ductal adenocarcinoma

<table>
<thead>
<tr>
<th>Inducers</th>
<th>Target</th>
<th>Inhibited by</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erastin</td>
<td>System XC-/GPX4</td>
<td>CPX</td>
<td>Yang et al[18]</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>System XC-</td>
<td>β-ME, CHX, DFO, Fer-1, NAC, or Trolox</td>
<td>Kim et al[38,68]</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>System XC-</td>
<td>DFO, Fer-1, Trolox, or VE</td>
<td>Lachaier et al[37]</td>
</tr>
<tr>
<td>Artesunate</td>
<td>System XC-</td>
<td>DFO or Fer-1</td>
<td>Xie et al[9]</td>
</tr>
<tr>
<td>RSL3</td>
<td>GPX4</td>
<td>CPX, DFO, Ebs, Fer-1, Lip-1, Trolox, or U0126</td>
<td>Yang et al[18]</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>GPX4</td>
<td>Lip-1</td>
<td>Liu et al[60]</td>
</tr>
<tr>
<td>FIN56</td>
<td>GPX4</td>
<td>DFO, BSO and α-Toc</td>
<td>Liang et al[68]</td>
</tr>
<tr>
<td>FNO2</td>
<td>GPX4/Iron</td>
<td>β-ME or Fer-1</td>
<td>Liang et al[68]</td>
</tr>
<tr>
<td>Piperlongumine</td>
<td>GPX4</td>
<td>Fer-1, lip-1, CPX and DFO</td>
<td>Yamaguchi et al[63]</td>
</tr>
<tr>
<td>Ruscogenin</td>
<td>Iron</td>
<td>DFO, FAC</td>
<td>Song et al[59]</td>
</tr>
<tr>
<td>Irisin</td>
<td>Iron, ROS, and glutathione depletion</td>
<td>Not mentioned</td>
<td>Yang et al[64]</td>
</tr>
</tbody>
</table>

α-Toc: α-tocopherol; β-ME: β-mercaptoethanol; BSO: Buthionine sulfoximine; CHX: Cycloheximide; CPX: Ciclopirox olamine; DFO: Iron chelator deferoxamine; Ebs: Ebselen; FAC: Ferric ammonium citrate. Fer-1: Ferrostatin-1; Lip-1: Liproxstatin-1; NAC: N-acetylcysteine; VE: Vitamin E.

It has been reported that erastin and its analogs (e.g., sulfasalazine and sorafenib) can block the transport function of system XC- and induce ferroptosis. Wang et al[39] studied the effect of system XC- on ferroptosis and found that branched-chain amino acid transaminase 2 (BCAT2) was the key enzyme mediating the metabolism of sulfur amino acids. BCAT2 was found to regulate intracellular glutamate concentration and its activation by ectopic expression specifically antagonized the inhibition of system XC- and protected PDAC cells from ferroptosis in vitro and in vivo. Furthermore, BCAT2 participates in the synergistic mechanisms of sulfasalazine and sorafenib to induce ferroptosis. Therefore, BCAT2 may be considered a suppressor of ferroptosis, and inhibiting intracellular glutamate synthesis might be effective in inducing ferroptosis.

Another small molecule, RSL3 directly inhibits GPX4, leading to the accumulation of lipid ROS and ferroptosis. Selenium increases the antiferroptotic activity of GPX4 through a selenocysteine residue at 46. In addition, selenium is incorporated during the synthesis of selenoproteins such as thioredoxin reductase 1 (TrxR1; direct reduction of hydroperoxides). Rong et al[45] reported that diaphanous homolog 3 (DIAPH3) was highly expressed in the tissues of patients with PDAC, wherein it promoted an increase of selenium content and interacted with the selenoprotein, ribosomal protein L6. DIAPH3 downregulated cellular ROS levels by upregulating the expression of TrxR1.

**Ferroptosis regulated by lipid metabolism in PDAC**

Fatty acids are substrates of lipid peroxidation reactions, and are esterified to form membrane phospholipids. PUFAs are more prone to oxidation than either saturated or monounsaturated fatty acids (MUFAs). Membrane phospholipids react with oxygen and adjacent lipids to generate phospholipid hydroperoxide (PL-OOH). The reaction product of Fe²⁺ and PL-OOH continues to react with lipids to generate phospholipid radicals for a new round of lipid peroxidation[46]. The degradation products of PL-OOH damage the cell membrane. Extensive lipid peroxidation affects the fluidity and structure of the cell membrane, increases its permeability, and leads to cell death. Lipid peroxidation is catalyzed by long-chain acyl-CoA synthetase 4 (ACSL4), lysophosphatidylcholine acyltransferase 3 (LPCAT3), and arachidonate lipoxygenase (ALOX). ACSL4 catalyzes lipid reactions and tends to esterify the acyl group of arachidonic acid, while LPCAT3 aids in the insertion of PUFA into membrane phospholipids. Subsequently, free PUFAs are catalyzed by ALOXs to produce various lipid hydrogen peroxides[47,48].

Lipid peroxides cause cellular damage through several mechanisms. The first is by the decomposition of lipid peroxides into ROS, which further amplifies the lipid peroxidation process. Second, lipid peroxides alter the physical structure of the membrane, with changes in thickness, the degree of curvature, and pore formation.
that results in the release of harmful substances and disrupting intracellular metabolism. The third is via by-products such as malondialdehyde and 4-hydroxy-2-nonenal produced by lipid peroxidation, which can damage the cells[48]. ADP ribosylation factor 6 (ARF6) is a member of the RAS superfamily and regulates vesicular trafficking, remodeling of membrane lipids, and signaling pathways. A study reported that ARF6 regulated the sensitivity to RSL3-induced ferroptosis and enhanced RSL3-induced lipid peroxidation by affecting the level of ACSL4 protein [49]. ALOX5 is the functional subtype of the ALOX family. It catalyzes the peroxidation of PUFA's such as arachidonic acid and is a key mediator of lipid peroxidation [50]. Kuang et al[51] observed that NRF2 mediated the upregulation of microsomal glutathione transferase 1, which by binding to ALOX5, limited lipid peroxidation during ferroptosis in PDAC. p53 protein is a transcription factor that has an important role in preventing the development of PDAC. In addition to being regulated by a variety of cellular stressors and as a master regulator, p53 is involved in the arrest of cell growth, apoptosis, and senescence. Recently, p53 has been found to regulate a variety of cellular metabolic functions and the stress response to ROS[52]. Ou et al [53] discovered that p53 stimulated ferroptosis by directly activating expression of its target gene spermidine/spermine N1-acetyltransferase 1, which triggers ferroptosis upon stress from ROS. The activity of PUFA's in ferroptosis is competitively affected by MUFA's, indicating that exogenous MUFA's cause resistance to ferroptosis. The resistance depends on ACSL3 or stearoyl-CoA desaturase (SCD/SCD1), an enzyme involved in fatty acid biosynthesis, primarily the synthesis of oleic acid[35]. Ye et al[54] found that F-box and WD repeat domain-containing 7 promoted both ferroptosis and apoptosis in PDAC by downregulating SCD1 and inhibited the transcription of SCD1 by reducing the binding of NR4A1 to the SCD1 promoter.

**Ferroptosis is regulated by the tumor microenvironment in PDAC**

The tumor microenvironment, including the tumor cells, vascular system, extracellular matrix, and immune cells, is an important factor affecting the outcomes of therapy. It has been reported that nano-inducers of ferroptosis attract iron from the extracellular environment to increase the intracellular content. It has also been shown that simultaneous upregulation of FHC and downregulation of GSH that increased the levels of intracellular ROS led to ferroptosis in tumor cells[53]. Another inducer is a near-infrared photosensitizer, IR780, which can be loaded into perfluorocarbon nanodroplets. The function of the inducer functions depends on differences of the microenvironments of normal and tumor tissue such as oxygen level, pH, and the immune system, among other factors. Photodynamic therapy activated oxygen enriched with perfluorocarbon generated ROS in the tumor tissue to kill the tumor cells [56]. Traditionally, CD8+ T cells in the tumor microenvironment induce cell death through perforin, granzyme, and Fas/Fas ligand pathways. However, a recent study demonstrated that immunotherapy-activated CD8+ T cells enhanced ferroptosis-specific lipid peroxidation in tumor cells. Interferon-gamma released from CD8+ T cells was found to downregulate the expression of SLC3A2 and SLC7A11, restrain cystine uptake in tumor cells, and promote lipid peroxidation and ferroptosis[57]. In addition, various macrophage subsets have different sensitivities to ferroptosis. Resting macrophages can be polarized to form antitumor M1 and procarcinogenic M2 subtypes. Dai et al[58] reported that KRASG12D caused macrophages to switch to an M2-like pro-tumor phenotype via signal transducer and activator of transcription 3-dependent fatty acid oxidation, which can be considered a key mediator of cancer cell-macrophage communication in PDAC. Furthermore, oxidative stress induced the release of KRASG12D protein from cancer cells undergoing ferroptosis. Targeting the tumor microenvironment to promote ferroptosis of PDAC cells could be a new strategy for cancer therapy (Figure 3).

**INDUCING FERROPTOSIS TO TREAT PDAC**

Ferroptosis has an important role in tumor cell death and inhibition of tumor growth; therefore, inducing ferroptosis in PDAC is expected to become a new therapeutic strategy. Inducers of ferroptosis can be divided into several categories based on the regulatory mechanism.

**Iron metabolism**

Song et al[59] reported that ruscogenin induced ferroptosis by regulating the levels of transferrin and ferroportin. Ruscogenin increased the concentration of intracellular...
Fe$^{2+}$ and the production of ROS, which was inhibited by deferoxamine.

**Ferritinophagy**
Liu et al[60] observed that rapamycin caused autophagy-dependent ferroptosis by inducing the degradation of GPX4 protein but did not inhibit GPX4 gene transcription. In animal studies, the researchers observed that GPX4 depletion in PDAC cells enhanced the anticancer activity of rapamycin in vivo. Li et al[61] proposed a new model of cell death, wherein mitochondrial DNA stress triggered autophagy-dependent ferroptosis. Degradation of zalcitabine-induced transcription factor A, mitochondrial triggered oxidative DNA damage, the release of mitochondrial DNA into the cytosol, and subsequent activation of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway. Zalcitabine suppressed pancreatic tumor growth via the autophagy-dependent ferroptosis.

**Lipid metabolism**
Several key enzymes (ACSL4, LPCAT3, and ALOXs) are involved in lipid oxidation and can be regulated to induce ferroptosis. Studies have reported that erastin and RSL3 induced ferroptosis in PDAC[62], and ALOXs enhanced the sensitivity of RAS-mutated tumor cells to erastin and RSL3[50].

**Amino acid metabolism**
Piperlongumine (PL) is a natural product with cytotoxic properties restricted to cancer cells. PL acts by significantly increasing ROS levels in an iron-dependent manner. Yamaguchi et al[63] found that PL rapidly induced the death of human PDAC cells chiefly through the inhibition of GPX4, and sulfasalazine enhanced cell death. Moreover, sulfasalazine enhanced the cancer cell-killing ability of the combination of PL and cotylenin A, which is a plant growth regulator with potent antitumor activity.

**Comprehensive regulation**
Bao et al[64] investigated the effects of irisin on the expression of the ROS-related protein NRF2 and the autophagy-related protein, microtubule-associated protein 1A/1B-light chain 3 during ferroptosis. They observed that irisin promoted the up-regulation of erastin-induced free iron, lipid ROS, and GSH depletion and positively regulated ferroptosis in PDAC. Eling et al[65] reported that artesunate (ART) was a specific activator of ferroptosis in PDAC cells and that erastin and ART activated ferroptosis in PDAC cell lines in an iron- and ROS-dependent manner. ART-induced ferroptosis was most effective in mutationally-active KRAS expressing PDAC cell lines. Subsequently, Wang et al[66] showed that inhibition of 78-kDa glucose-regulated protein 78 reversed the resistance of PDAC cells to ferroptosis and increased tumor sensitivity to ART.
CONCLUSION
Ferroptosis is a new model of cell death induced by small molecules such as erastin and RSL3, which are regulated at multiple levels. In this review, we briefly described the mechanism of ferroptosis, which includes iron, amino acid, and lipid metabolism, and summarized the regulatory pathways of ferroptosis in PDAC. The occurrence and development of ferroptosis are accompanied by the accumulation of ROS, resulting in lipid peroxidation of the cell membrane. Inducing ferroptosis can cause the death of PDAC cells, and can have a synergistic role with anticancer drugs to improve the sensitivity of PDAC to the existing treatment modalities. In addition, the level of ferroptosis inducer is associated with the prognosis of the disease. Therefore, induction of ferroptosis may have potential as a treatment of PDAC. However, ferroptosis has not been studied extensively in PDAC. A study reported that knockout of the GPX4 gene in B1 and marginal zone B cells triggered ferroptosis by inducing lipid peroxidation, thus affecting the immune response of B cells[67]. However, there are no studies of B cells and ferroptosis in PDAC. Therefore, clarification of the molecular mechanism of ferroptosis and exploration of its role in the development and treatment of PDAC will help explain not only the mechanism of cell death and escape of PDAC cells, but also to develop novel effective therapeutic targets.

REFERENCES
28
27
26
25
22
21
19
18
15
12
11

Thévenod F

Sun X

Gastroenterol

Graham RM

glutathione-independent ferroptosis suppressor.

Schulze A, O'Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli JPF, Conrad M. FSP1 is a

Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W,

Doll S


Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor

agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003;

3: 285-296 [PMID: 12676856 DOI: 10.1016/s1355-6108(03)00050-3]

Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent,


[PMID: 18355723 DOI: 10.1016/j.chembio.2008.02.010]

Tang D, Kang R, Berghé TV, Vandenbergbe P, Kroemer G. The molecular machinery of regulated


Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Almenri ES, Altucci L,

Amelio I, Andrews DW, Ammirato-Petruzzelli M, Antonov AG, Arasu RA, Baeber EE, Barlev

NA, Bazan NG, Bernasolla F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blongren K, Borner C,

Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chen FK, Chandel


Czabotar PE, D’Angioluella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin K,

Deberardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS,

Dynlacht BD, El-Deiry WS, Elrod JW, Elrod-Varn et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.
Yang Y et al. Ferroptosis in pancreatic cancer

18 [PMID: 29394034 DOI: 10.1515/9783110470734-021]
Ferroptosis in pancreatic cancer

Yang Y et al. Ferroptosis in pancreatic cancer

10.1155/2019/2749173


